Evidence map›Paper›PMID 37321962›Full record

Observational studyEuropean heart journal. Quality of care & clinical outcomes2024

Association of cancer with the risk of developing hypertension.

Hajime Nagasawa, Hidehiro Kaneko, Yuta Suzuki, Akira Okada, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Yuichiro Yano, Koichi Node and 6 more

Open access · hybridAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in European heart journal. Quality of care & clinical outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Current Status and Future Perspective of Onco-Hypertension.American journal of hypertension · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Hajime NagasawaThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Hidehiro KanekoThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-2553-6170
Yuta SuzukiThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Akira OkadaDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Katsuhito FujiuThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Norifumi TakedaThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki MoritaThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Yuichiro YanoNoncommunicable Disease (NCD) Epidemiology Research Center, Shiga University of Medical Science, Shiga, Japan.ORCID 0000-0002-2565-7290
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.ORCID 0000-0002-2534-0939
Anthony J VieraDepartment of Family Medicine and Community Health, Duke University, Durham, NC, USA.
Robert M CareyDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.
Suzanne OparilDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-7505-2599
Hideo YasunagaThe Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Rhian M TouyzResearch Institute, McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0003-0670-0887
Issei KomuroThe Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0714-7182
The University of Tokyo · JPDuke University · USJuntendo University · JPKagawa University · JPMcGill University Health Centre · CANational Institute of Public Health · JPSaga University · JPShiga University of Medical Science · JPUniversity of Alabama at Birmingham · USUniversity of Virginia · US

Funding

Ministry of Education, Culture, Sports, Science and Technology 17H04141Ministry of Health, Labour and Welfare 19AA2007
6 · The paper itself

Abstract

BACKGROUND AND

aimsAlthough the importance of hypertension in patients with cancer is widely recognized, little is known about the risk of developing hypertension in patients with a history of cancer. METHODS AND

resultsThis retrospective observational cohort study analysed data from the JMDC Claims Database between 2005 and 2022, including 78 162 patients with a history of cancer and 3692 654 individuals without cancer. The primary endpoint was the incidence of hypertension.During a mean follow-up period of 1208 ± 966 days, 311 197 participants developed hypertension. The incidence of hypertension was 364.6 [95% confidence interval (CI) 357.0-372.2] per 10 000 person-years among those with a history of cancer, and 247.2 (95% CI 246.3-248.1) per 10 000 person-years in those without cancer. Individuals with a history of cancer had an elevated risk of developing hypertension, according to multivariable Cox regression analyses [hazard ratio (HR) 1.17, 95% CI 1.15-1.20]. Both cancer patients requiring active antineoplastic therapy (HR 2.01, 95% CI 1.85-2.20), and those who did not require active antineoplastic therapy (HR 1.14, 95% CI 1.12-1.17) had an increased risk of hypertension. A multitude of sensitivity analyses confirmed the robustness of the relationship between cancer and incident hypertension. Patients with certain types of cancer were found to have a higher risk of developing hypertension than those without cancer, with varying risks dependent on the type of cancer.

conclusionOur analysis of a nationwide epidemiological database revealed that individuals with a history of cancer have a higher risk of developing hypertension, and this finding applies to both cancer patients who require active antineoplastic therapy and those who do not.

Indexed as

HypertensionNeoplasmsAdultAgedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsCancerEpidemiologyHypertension

Identifiers

PMID37321962
PMCPMC11112520
OpenAlexW4380737992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.